序贯ALK抑制剂可筛选出对洛拉替尼耐药的复合ALK突变
该研究通过ENU诱变筛选EML4-ALK Ba/F3细胞,发现单次ALK突变不导致洛拉替尼耐药,而复合ALK突变可在洛拉替尼耐药克隆中出现;20例洛拉替尼耐药患者活检中7例(35%)携带复合ALK突变,3例外显子组测序证实序贯治疗中ALK突变逐步累积。提示序贯ALK抑制剂可促进复合耐药突变出现。
要点
- 单次ALK突变不导致洛拉替尼耐药,复合ALK突变介导高水平耐药。
- 洛拉替尼耐药患者活检中35%(7/20)检出复合ALK突变。
- 序贯第一、二、三代ALK抑制剂可筛选出复合ALK突变。
核心结论
- 序贯使用第一、二、三代ALK抑制剂可筛选出对ALK靶向治疗高水平耐药的复合ALK突变。
研究设计与样本
- 对表达EML4-ALK的Ba/F3细胞进行加速诱变筛选,并在含单ALK耐药突变的EML4-ALK背景下进行类似筛选。
- 分析洛拉替尼耐药患者的重复活检,并对3例进行全外显子组测序。
主要发现
- 在可比条件下,ENU诱变产生大量携带单ALK突变的克唑替尼耐药克隆,但未产生洛拉替尼耐药克隆。
- 在含单ALK耐药突变的EML4-ALK筛选中,出现大量携带复合ALK突变的洛拉替尼耐药克隆。
- 20例洛拉替尼耐药患者活检中7例(35%)携带复合ALK突变,其中两种突变也在ENU筛选中发现。
- 3例全外显子组测序证实序贯治疗期间ALK突变逐步累积。
临床怎么用
- 对洛拉替尼耐药患者应关注复合ALK突变,其可导致对ALK靶向治疗的高水平耐药。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
The cornerstone of treatment for advanced ALK-positive lung cancer is sequential therapy with increasingly potent and selective ALK inhibitors. The third-generation ALK inhibitor lorlatinib has demonstrated clinical activity in patients who failed previous ALK inhibitors. To define the spectrum of ALK mutations that confer lorlatinib resistance, we performed accelerated mutagenesis screening of Ba/F3 cells expressing EML4-ALK. Under comparable conditions, N-ethyl-N-nitrosourea (ENU) mutagenesis generated numerous crizotinib-resistant but no lorlatinib-resistant clones harboring single ALK mutations. In similar screens with EML4-ALK containing single ALK resistance mutations, numerous lorlatinib-resistant clones emerged harboring compound ALK mutations. To determine the clinical relevance of these mutations, we analyzed repeat biopsies from lorlatinib-resistant patients. Seven of 20 samples (35%) harbored compound ALK mutations, including two identified in the ENU screen. Whole-exome sequencing in three cases confirmed the stepwise accumulation of ALK mutations during sequential treatment. These results suggest that sequential ALK inhibitors can foster the emergence of compound ALK mutations, identification of which is critical to informing drug design and developing effective therapeutic strategies.Significance: Treatment with sequential first-, second-, and third-generation ALK inhibitors can select for compound ALK mutations that confer high-level resistance to ALK-targeted therapies. A more efficacious long-term strategy may be up-front treatment with a third-generation ALK inhibitor to prevent the emergence of on-target resistance. Cancer Discov; 8(6); 714-29. ©2018 AACR.This article is highlighted in the In This Issue feature, p. 663.
引用
- Yoda S, Lin JJ, Lawrence MS, et al. Sequential ALK Inhibitors Can Select for Lorlatinib-Resistant Compound ALK Mutations in ALK-Positive Lung Cancer. Cancer Discov. 2018. PMID: 29650534. doi:10.1158/2159-8290.CD-17-1256
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。